CGM Support for Association Members: A Vital Investment in Health Insurance Savings and Diabetes Complication Prevention

The Korean Diabetes Association is calling for an immediate expansion of health insurance coverage for Continuous Glucose Monitoring (CGM) devices to include all patients currently treated with insulin. According to the organization, the current reimbursement policy leaves a significant number of patients vulnerable to preventable health complications, including severe hypoglycemia, kidney failure requiring dialysis, vision loss, and limb amputation.

As an internal medicine physician, I have seen firsthand how diabetes management requires precision. The association argues that treating CGM support as a mandatory medical necessity—rather than an optional expense—is a strategic investment. By enabling real-time glucose tracking, the health system can avoid the high long-term costs associated with managing advanced diabetes-related complications, effectively reducing the burden on the national health insurance fund. This push comes as medical professionals continue to emphasize the role of digital health technology in stabilizing blood glucose levels for insulin-dependent populations.

The Clinical Necessity of Continuous Glucose Monitoring

Continuous Glucose Monitoring (CGM) systems provide users with real-time data on their blood sugar levels, alerting them to dangerous fluctuations before they result in emergency situations. In South Korea, the Ministry of Health and Welfare has gradually expanded coverage for these devices, but the Korean Diabetes Association maintains that the criteria remain too restrictive for the broader population of patients who rely on daily insulin injections.

Clinical data consistently shows that consistent monitoring reduces the frequency of hypoglycemia, or low blood sugar, which is a leading cause of acute emergency room visits for diabetic patients. For a patient managing insulin therapy, these trends are critical for adjusting dosages and preventing the long-term systemic damage that leads to retinopathy, nephropathy, and peripheral neuropathy.

Economic Arguments for Expanded Coverage

The Korean Diabetes Association’s stance is that the upfront cost of subsidizing CGM devices is offset by the reduction in catastrophic health expenditures. When patients can proactively manage their glucose levels, the incidence of hospitalization for diabetic ketoacidosis and severe hypoglycemic shock decreases significantly.

Public health policy in South Korea is governed by the National Health Insurance Service (NHIS), which periodically reviews the inclusion of medical devices based on clinical efficacy and cost-effectiveness. The association is positioning its request as a fiscal strategy, noting that the long-term care costs for a patient requiring dialysis or surgery due to diabetic complications far exceed the annual cost of providing a CGM device. Similar arguments have been made by international health bodies, such as the World Health Organization, which emphasizes that early intervention and access to essential diabetes technology are cornerstones of sustainable healthcare systems.

Current Status and Future Policy Outlook

While the demand for broader coverage grows, the policy process remains subject to rigorous review by the Health Insurance Policy Deliberation Committee. Patients and providers are currently monitoring these discussions to see if the criteria for “insulin-treated patients” will be expanded in the upcoming fiscal year.

For patients currently navigating the system, information on existing support programs and eligibility criteria for medical device reimbursement can be found through the National Health Insurance Service (NHIS) official website. As of this writing, no official date has been set for a legislative change regarding universal coverage for all insulin-dependent patients. The medical community continues to advocate for a framework that prioritizes patient safety and long-term health outcomes through the adoption of digital monitoring tools.

We will continue to monitor updates from the Ministry of Health and Welfare and the Korean Diabetes Association as they pertain to these reimbursement policies. If you have questions regarding how these potential changes might affect your care plan, I encourage you to consult with your primary endocrinologist to discuss the most recent clinical guidelines and available monitoring options.